The Manufacturers Life Insurance Company Has $19.79 Million Stock Holdings in Axsome Therapeutics, Inc. $AXSM

Posted by Geri Gentry on Aug 2nd, 2026

The Manufacturers Life Insurance Company decreased its holdings in shares of Axsome Therapeutics, Inc. (NASDAQ:AXSM – Free Report) by 12.5% in the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 117,093 shares of the company’s stock after selling 16,791 shares during the period. The Manufacturers Life Insurance Company’s holdings in Axsome Therapeutics were worth $19,791,000 as of its most recent SEC filing.

Other institutional investors also recently added to or reduced their stakes in the company. Price T Rowe Associates Inc. MD raised its holdings in shares of Axsome Therapeutics by 45.5% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 1,509,870 shares of the company’s stock worth $275,763,000 after buying an additional 472,422 shares in the last quarter. Wellington Management Group LLP boosted its stake in Axsome Therapeutics by 84.1% in the 3rd quarter. Wellington Management Group LLP now owns 1,334,560 shares of the company’s stock valued at $162,082,000 after buying an additional 609,516 shares in the last quarter. Invesco Ltd. grew its position in Axsome Therapeutics by 28.6% in the fourth quarter. Invesco Ltd. now owns 1,273,494 shares of the company’s stock valued at $232,591,000 after acquiring an additional 282,937 shares during the period. Geode Capital Management LLC raised its stake in Axsome Therapeutics by 1.3% during the fourth quarter. Geode Capital Management LLC now owns 1,010,249 shares of the company’s stock worth $184,544,000 after acquiring an additional 12,549 shares in the last quarter. Finally, State Street Corp lifted its holdings in shares of Axsome Therapeutics by 5.8% during the second quarter. State Street Corp now owns 958,503 shares of the company’s stock valued at $100,058,000 after acquiring an additional 52,483 shares during the period. 81.49% of the stock is owned by institutional investors and hedge funds.

Insider Activity

In other Axsome Therapeutics news, Director Susan Mahony sold 300 shares of the company’s stock in a transaction that occurred on Tuesday, June 9th. The shares were sold at an average price of $237.21, for a total value of $71,163.00. Following the completion of the sale, the director owned 1,129 shares of the company’s stock, valued at approximately $267,810.09. This represents a 20.99% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CFO Nick Pizzie sold 33,000 shares of the stock in a transaction on Tuesday, June 9th. The stock was sold at an average price of $240.09, for a total transaction of $7,922,970.00. Following the completion of the sale, the chief financial officer owned 42,867 shares in the company, valued at approximately $10,291,938.03. This trade represents a 43.50% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last 90 days, insiders have sold 155,852 shares of company stock valued at $37,230,112. Insiders own 20.60% of the company’s stock.

Axsome Therapeutics Trading Down 7.1%

AXSM opened at $217.99 on Friday. The company has a debt-to-equity ratio of 2.27, a current ratio of 1.39 and a quick ratio of 1.32. The company has a market cap of $11.22 billion, a price-to-earnings ratio of -58.44 and a beta of 0.60. The firm has a 50 day simple moving average of $239.21 and a 200 day simple moving average of $202.71. Axsome Therapeutics, Inc. has a fifty-two week low of $96.09 and a fifty-two week high of $260.19.

Axsome Therapeutics (NASDAQ:AXSM – Get Free Report) last announced its quarterly earnings data on Monday, May 4th. The company reported ($1.26) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.85) by ($0.41). Axsome Therapeutics had a negative net margin of 26.59% and a negative return on equity of 267.16%. The business had revenue of $191.20 million during the quarter, compared to the consensus estimate of $191.10 million. The firm’s revenue was up 57.4% compared to the same quarter last year. On average, sell-side analysts anticipate that Axsome Therapeutics, Inc. will post -2.45 earnings per share for the current year.

Wall Street Analyst Weigh In

Several analysts have weighed in on AXSM shares. Wells Fargo & Company upped their price objective on shares of Axsome Therapeutics from $225.00 to $255.00 and gave the stock an “overweight” rating in a research note on Tuesday, May 5th. Mizuho decreased their price target on Axsome Therapeutics from $310.00 to $306.00 and set an “outperform” rating on the stock in a research report on Friday. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $272.00 price target on shares of Axsome Therapeutics in a report on Monday, May 4th. BMO Capital Markets assumed coverage on Axsome Therapeutics in a research note on Monday, July 20th. They issued an “outperform” rating and a $310.00 target price for the company. Finally, Piper Sandler reaffirmed an “overweight” rating and issued a $258.00 price target on shares of Axsome Therapeutics in a report on Monday, May 4th. Two equities research analysts have rated the stock with a Strong Buy rating, nineteen have issued a Buy rating and two have given a Sell rating to the company. According to data from MarketBeat.com, Axsome Therapeutics currently has a consensus rating of “Moderate Buy” and a consensus target price of $261.29.

View Our Latest Report on AXSM

Axsome Therapeutics Company Profile

(Free Report)

Axsome Therapeutics, Inc is a clinical-stage biopharmaceutical company dedicated to developing novel therapies for central nervous system (CNS) disorders. The company focuses on small-molecule drugs designed to address unmet medical needs in areas such as depression, migraine, narcolepsy and fibromyalgia. Axsome employs a precision medicine approach, leveraging pharmacologic innovation to target underlying mechanisms of disease and improve patient outcomes.

Axsome’s pipeline includes several late-stage and approved product candidates.